Neuroprotective Effect Is Driven Through the Upregulation of CB1 Receptor in Experimental Autoimmune Encephalomyelitis

Journal of Molecular Neuroscience

Volumn 58, Issue 2, 2016, Pages 193-200

  Lou, Zhi Yin ^a   Yu, Wen Bo ^b   Chen, Jie ^a   Li, Lin ^a   Jiang, Li Sheng ^c   Xiao, Bao Guo ^b   Liu, Zhen Guo ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CB1 receptor; Experimental autoimmune encephalomyelitis; Inflammation; Lentiviral vectors; Neurotrophic factors

Indexed keywords

CANNABINOID 1 RECEPTOR; CD11B ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; LENTIVIRUS VECTOR; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN DERIVATIVE; NEUROTROPHIN 3; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; LUMBAR SPINAL CORD; MONONUCLEAR CELL; MOUSE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; GENETICS; METABOLISM; MONOCYTE; SPINAL CORD; SPLEEN;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELLS, CULTURED; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; INTERLEUKINS; MICE; MICE, INBRED C57BL; MONOCYTES; NEUROTROPHIN 3; NF-KAPPA B; RECEPTOR, CANNABINOID, CB1; SPINAL CORD; SPLEEN; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84958058015     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-015-0656-9     Document Type: Article

References (28)

1. Arima Y, Harada M, Kamimura D, Park JH, Kawano F, Yull FE, Kawamoto T, Iwakura Y, Betz UA, Márquez G, Blackwell TS, Ohira Y, Hirano T, Murakami M (2012) Regional neural activation defines a gateway for autoreactive T cells to cross the blood–brain barrier. Cell 148:447–457
2. Butovsky E, Juknat A, Goncharov I, Elbaz J, Eilam R, Zangen A, Vogel Z (2005) In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to delta-tetrahydrocannabinol. J Neurochem 93:802–811
3. Comi G (2013) Disease-modifying treatments for progressive multiple sclerosis. Mult Scler 19:1428–1436
4. Conti AC, Cryan JF, Dalvi A, Lucki I, Blendy JA (2002) CAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or neuroendocrine responses to antidepressant drugs. J Neurosci 22:3262–3268
5. De Chiara V, Angelucci F, Rossi S, Musella A, Cavasinni F, Cantarella C, Mataluni G, Sacchetti L, Napolitano F, Castelli M, Caltagirone C, Bernardi G, Maccarrone M, Usiello A, Centonze D (2010) Brain-derived neurotrophic factor controls cannabinoid CB1 receptor function in the striatum. J Neurosci 30:8127–8137
6. de Lago E, Moreno-Martet M, Cabranes A, Ramos JA, Fernández-Ruiz J (2012) Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. Neuropharmacology 62:2299–2308
7. De Santi L, Polimeni G, Cuzzocrea S, Esposito E, Sessa E, Annunziata P, Bramanti P (2011) Neuroinflammation and neuroprotection: an update on (future) neurotrophin-related strategies in multiple sclerosis treatment. Curr Med Chem 18:1775–1784
8. Duman RS (2002) Pathophysiology of depression: the concept of synaptic plasticity. Eur Psychiatry 17:306–310
9. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87:1932–1936
10. Hong J, Nandiwada V, Jones V, Lu M, Warner DS, Mukhopadhyay S, Sheng H (2015) CB1 cannabinoid receptor agonist inhibits matrix metalloproteinase activity in spinal cord injury: a possible mechanism of improved recovery. Neurosci Lett 597:19–24
11. Huang EJ, Reichardt LF (2001) Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24:677–736
12. Jockers-Scherübl MC, Danker-Hopfe H, Mahlberg R, Selig F, Rentzsch J, Schürer F, Lang UE, Hellweg R (2004) Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse. Neurosci Lett 371:79–83
13. Kaplan BL (2013) The role of CB1 in immune modulation by cannabinoids. Pharmacol Ther 137:365–374
14. Lou ZY, Zhao CB, Xiao BG (2012) Immunoregulation of experimental autoimmune encephalomyelitis by the selective CB1 receptor antagonist. J Neurosci Res 90:84–95
15. Maghzi AH, Minagar A, Waubant E (2013) Neuroprotection in multiple sclerosis: a therapeutic approach. CNS Drugs 27:799–815
16. Mahad DH, Trapp BD, Lassmann H (2015) Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 14:183–193
17. Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng X, Carrier EJ, Mann MK, Giovannoni G, Pertwee RG, Yamamura T, Buckley NE, Hillard CJ, Lutz B, Baker D, Dittel BN (2007) Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 13:492–497
18. Maroof N, Pardon MC, Kendall DA (2013) Endocannabinoid signalling in Alzheimer’s disease. Biochem Soc Trans 41:1583–1587
19. Miller LK, Devi LA (2011) The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol Rev 63:461–470
20. More SV, Choi DK (2015) Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection. Mol Neurodegener 10:17
21. Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4:873–884
22. Ponomarev ED, Shriver LP, Maresz K, Dittel BN (2005) Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. J Neurosci Res 81:374–389
23. Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A, Thompson AJ, Giovannoni G, Cuzner ML, Baker D (2003) Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126:2191–2202
24. Pryce G, Riddall DR, Selwood DL, Giovannoni G, Baker D (2014) Neuroprotection in experimental autoimmune encephalomyelitis and progressive multiple sclerosis by cannabis-based cannabinoids. J Neuroimmune Pharmacol
25. Rossi S, Furlan R, De Chiara V, Muzio L, Musella A, Motta C, Studer V, Cavasinni F, Bernardi G, Martino G, Cravatt BF, Lutz B, Maccarrone M, Centonze D (2011) Cannabinoid CB1 receptors regulate neuronal TNF-α effects in experimental autoimmune encephalomyelitis. Brain Behav Immun 25:1242–1248
26. Schmidt W, Schäfer F, Striggow V, Fröhlich K, Striggow F (2012) Cannabinoid receptor subtypes 1 and 2 mediate long-lasting neuroprotection and improve motor behavior deficits after transient focal cerebral ischemia. Neuroscience 227:313–326
27. Tomiyama K, Funada M (2014) Cytotoxicity of synthetic cannabinoids on primary neuronal cells of the forebrain: the involvement of cannabinoid CB1 receptors and apoptotic cell death. Toxicol Appl Pharmacol 274:17–23
28. Zhao L, Levine ES (2014) BDNF-endocannabinoid interactions at neocortical inhibitory synapses require phospholipase C signaling. J Neurophysiol 111:1008–1015